Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.07 - $1.75 $63,558 - $103,950
59,400 Added 29.8%
258,700 $305,000
Q2 2024

Aug 14, 2024

BUY
$0.75 - $1.31 $36,675 - $64,059
48,900 Added 32.51%
199,300 $247,000
Q1 2024

May 15, 2024

SELL
$0.79 - $1.14 $181,682 - $262,174
-229,978 Reduced 60.46%
150,400 $144,000
Q4 2023

Feb 14, 2024

SELL
$1.02 - $2.57 $155,782 - $392,510
-152,728 Reduced 28.65%
380,378 $407,000
Q3 2023

Nov 14, 2023

BUY
$2.52 - $5.69 $215,979 - $487,667
85,706 Added 19.16%
533,106 $1.36 Million
Q2 2023

Aug 14, 2023

BUY
$5.0 - $7.66 $751,500 - $1.15 Million
150,300 Added 50.59%
447,400 $2.42 Million
Q1 2023

May 15, 2023

BUY
$3.54 - $6.66 $535,956 - $1.01 Million
151,400 Added 103.91%
297,100 $1.89 Million
Q4 2022

Feb 14, 2023

SELL
$2.11 - $4.3 $123,224 - $251,120
-58,400 Reduced 28.61%
145,700 $626,000
Q3 2022

Nov 14, 2022

BUY
$2.13 - $4.0 $60,705 - $114,000
28,500 Added 16.23%
204,100 $463,000

Others Institutions Holding ASRT

About Assertio Holdings, Inc.


  • Ticker ASRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 48,178,200
  • Market Cap $45.3M
  • Description
  • Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing sp...
More about ASRT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.